These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39266969)

  • 1. Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine.
    Mvula M; Mtonga F; Mandolo J; Jowati C; Kalirani A; Chigamba P; Lisimba E; Mitole N; Chibwana MG; Jambo KC
    BMC Infect Dis; 2024 Sep; 24(1):959. PubMed ID: 39266969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.
    Zhang XS; Windau A; Meyers J; Yang X; Dong F
    Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study.
    Gütlin Y; Albertos Torres D; Gensch A; Schlotterbeck AK; Stöger L; Heller S; Infanti L; Barut GT; Thiel V; Leuzinger K; Hirsch HH; Buser A; Egli A
    Swiss Med Wkly; 2024 Jul; 154():3408. PubMed ID: 39137369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
    Liu S; van Dijk LLA; den Hartog Y; Hoek R; Verschuuren E; Geurtsvankessel CH; de Vries RD; Van Baarle D; Buter CVL
    Vaccine; 2024 Oct; 42(24):126250. PubMed ID: 39226789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants.
    Chalouni M; Loubet P; Lhomme E; Ninove L; Barrou B; Blay JY; Hourmant M; de Seze J; Laville M; Laviolle B; Lelièvre JD; Morel J; Quoc SN; Spano JP; Terrier B; Thiebaut A; Viallard JF; Vrtovsnik F; Circosta S; Barquin A; Gharib M; Tartour E; Parfait B; Thiébaut R; Meyer L; de Lamballerie X; Launay O; Wittkop L;
    BMC Infect Dis; 2024 Sep; 24(1):1049. PubMed ID: 39333909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
    Tunheim G; Fossum E; Robertson AH; Rø GØI; Chopra A; Vaage JT; Vikse EL; Kran AB; Magnus P; Trogstad L; Mjaaland S; Hungnes O; Lund-Johansen F
    BMC Infect Dis; 2024 Aug; 24(1):841. PubMed ID: 39164637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection.
    Holder KA; Ings DP; Fifield KE; Barnes DA; Barnable KA; Harnum DOA; Russell RS; Grant MD
    J Immunol; 2024 Oct; 213(8):1105-1114. PubMed ID: 39248629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Lawpoolsri S; Nanthapisal S; Jongkaewwattana A; Duangdee C; Kamolratanakul S; Luvira V; Thanthamnu N; Chantratita N; Thitithanyanont A; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2024 Jul; 42(19):3999-4010. PubMed ID: 38744598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid Immunity to SARS-CoV-2 During Pregnancy Provides More Durable Infant Antibody Responses Compared to Natural Infection Alone.
    LaCourse SM; Wetzler EA; Aurelio MC; Escudero JN; Selke SS; Greninger AL; Goecker EA; Barnes SR; Arnould IS; Pérez-Osorio AC; Richardson BA; Kachikis A; Englund JA; Drake AL
    J Infect Dis; 2024 Jun; 229(6):1728-1739. PubMed ID: 38128542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters.
    Zhou P; Watt J; Mai J; Cao H; Li Z; Chen Z; Duan R; Quan Y; Gingras AC; Rini JM; Hu J; Liu J
    Front Immunol; 2024; 15():1430928. PubMed ID: 39281669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination.
    Voss WN; Mallory MA; Byrne PO; Marchioni JM; Knudson SA; Powers JM; Leist SR; Dadonaite B; Townsend DR; Kain J; Huang Y; Satterwhite E; Castillo IN; Mattocks M; Paresi C; Munt JE; Scobey T; Seeger A; Premkumar L; Bloom JD; Georgiou G; McLellan JS; Baric RS; Lavinder JJ; Ippolito GC
    Cell Rep Med; 2024 Aug; 5(8):101668. PubMed ID: 39094579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    Inizan C; Courtot A; Sturmach C; Griffon AF; Biron A; Bruel T; Enouf V; Demaneuf T; Munier S; Schwartz O; Gourinat AC; Médevielle G; Jouan M; van der Werf S; Madec Y; Albert-Dunais V; Dupont-Rouzeyrol M
    PLoS Med; 2024 Sep; 21(9):e1004397. PubMed ID: 39325828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant.
    Petrovsky N
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
    Chibwana MG; Moyo-Gwete T; Kwatra G; Mandolo J; Hermanaus T; Motlou T; Mzindle N; Ayres F; Chaponda M; Tembo G; Mwenechanya P; Mitole N; Jassi C; Kamng'ona R; Afran L; Mzinza D; Mwandumba HC; Gordon SB; Jere K; Madhi S; Moore PL; Heyderman RS; Jambo KC
    BMC Med; 2022 Mar; 20(1):128. PubMed ID: 35346184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.
    De Bouver C; Bouziotis J; Wijtvliet VPWM; Ariën KK; Mariën J; Heyndrickx L; Couttenye MM; de Fijter HJW; Mestrez F; Treille S; Mat O; Collart F; Allard SD; Vingerhoets L; Moons P; Abramowicz D; De Winter BY; Pipeleers L; Wissing KM; Ledeganck KJ
    Virol J; 2024 Jun; 21(1):138. PubMed ID: 38872127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.